Bluebird bio Inc (NASDAQ:BLUE) — Market Cap & Net Worth
Market Cap & Net Worth: Bluebird bio Inc (BLUE)
Bluebird bio Inc (NASDAQ:BLUE) has a market capitalization of $48.67 Million ($48.67 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22076 globally and #4836 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bluebird bio Inc's stock price $4.97 by its total outstanding shares 9792460 (9.79 Million). Review Bluebird bio Inc debt and liabilities to assess the company's total debt and financial obligations.
Bluebird bio Inc Market Cap History: 2015 to 2025
Bluebird bio Inc's market capitalization history from 2015 to 2025. Data shows change from $407.10 Million to $48.67 Million (-21.81% CAGR).
Index Memberships
Bluebird bio Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.08 Trillion | 0.00% | #27 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #631 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2116 of 3165 |
Weight: Bluebird bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bluebird bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bluebird bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.97x
Bluebird bio Inc's market cap is 0.97 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $407.10 Million | $14.08 Million | -$166.78 Million | 28.92x | N/A |
| 2016 | $391.12 Million | $6.16 Million | -$263.51 Million | 63.55x | N/A |
| 2017 | $1.13 Billion | $35.43 Million | -$335.64 Million | 31.87x | N/A |
| 2018 | $628.84 Million | $54.58 Million | -$555.62 Million | 11.52x | N/A |
| 2019 | $556.26 Million | $44.67 Million | -$789.61 Million | 12.45x | N/A |
| 2020 | $274.29 Million | $250.73 Million | -$618.70 Million | 1.09x | N/A |
| 2021 | $97.83 Million | $3.66 Million | -$562.64 Million | 26.71x | N/A |
| 2022 | $67.76 Million | $3.60 Million | -$266.58 Million | 18.84x | N/A |
| 2023 | $13.51 Million | $29.50 Million | -$211.91 Million | 0.46x | N/A |
| 2024 | $81.67 Million | $83.81 Million | -$240.72 Million | 0.97x | N/A |
Competitor Companies of BLUE by Market Capitalization
Companies near Bluebird bio Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Bluebird bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Bluebird bio Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Bluebird bio Inc's market cap moved from $407.10 Million to $ 48.67 Million, with a yearly change of -21.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $48.67 Million | -40.41% |
| 2024 | $81.67 Million | +504.35% |
| 2023 | $13.51 Million | -80.06% |
| 2022 | $67.76 Million | -30.73% |
| 2021 | $97.83 Million | -64.34% |
| 2020 | $274.29 Million | -50.69% |
| 2019 | $556.26 Million | -11.54% |
| 2018 | $628.84 Million | -44.30% |
| 2017 | $1.13 Billion | +188.65% |
| 2016 | $391.12 Million | -3.92% |
| 2015 | $407.10 Million | -- |
End of Day Market Cap According to Different Sources
On May 29th, 2026 the market cap of Bluebird bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $48.67 Million USD |
| MoneyControl | $48.67 Million USD |
| MarketWatch | $48.67 Million USD |
| marketcap.company | $48.67 Million USD |
| Reuters | $48.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bluebird bio Inc
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disea… Read more